GEN News Highlights: Apr 14, 2011

Leica Microsystems and Definiens Ink Co-Marketing Agreement for Imaging and High-Content Analysis Products

(Page 1 of 1)

    Leica Microsystems and Definiens will co-market a range of Leica microscopy hardware such as the company’s TCS SP5 confocal imaging instrumentation and Definiens XD software for multidimensional image analysis in high-content screening. The companies will also host joint workshops and educational events under the co-marketing agreement.

    Leica recently released its first high-content screening automation package for confocal research microscopes, Leica HCS A, designed for automated imaging in multiple dimensions. The package enables experiments ranging from automated image recording routines to multidimensional high-content screening, with simultaneous image export for analysis by external software such as Definiens Developer XD.

    Definiens Developer XD enables automated analysis of cases that previously required manual segmentation. It is an integrated software development environment designed for the entire range of biomedical image analysis problems and works with any imaging modality as well as 2-D, 3-D, and time-lapse applications.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll